Literature DB >> 11522023

Release of soluble urokinase receptor from vascular cells.

T Chavakis1, A K Willuweit, F Lupu, K T Preissner, S M Kanse.   

Abstract

Urokinase-type plasminogen activator (uPA) and its cell surface-receptor (uPAR) regulate cellular functions linked to adhesion and migration and contribute to pericellular proteolysis in tissue remodelling processes. Soluble uPAR (suPAR) is present in the circulation, peritoneal and ascitic fluid and in the cystic fluid from ovarian cancer. We have investigated the origin and the vascular distribution of the soluble receptor, which accounts for 10-20% of the total receptor in vascular endothelial and smooth muscle cells. Phase separation analysis of the cell conditioned media with Triton X-114 indicated that suPAR associates with the aqueous phase, indicative of the absence of the glycolipid anchor. There was a polarized release of suPAR from cultured endothelial cells towards the basolateral direction, whereas the membrane-bound receptor was found preferentially on the apical surface. Both, uPAR and suPAR became upregulated 2-4 fold after activation of protein kinase C with phorbol ester, which required de-novo protein biosynthesis. Interleukin-1beta (IL-1beta), basic fibroblast growth factor (bFGF) or vascular endothelial growth factor increased suPAR release from endothelial cells, whereas platelet derived growth factor-BB, bFGF or IL-1beta stimulated suPAR release from vascular smooth muscle cells. Immune electron microscopy indicated that in atherosclerotic vessels (s)uPAR was observed on cell membranes as well as in the extracellular matrix. These findings indicate that (s)uPAR from vascular cells is upregulated by proangiogenic as well as proatherogenic growth factors and cytokines, is preferentially released towards the basolateral side of endothelial cells and accumulates in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522023

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

Review 1.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

2.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

3.  Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression.

Authors:  Jinling Yang; Elia J Duh; Ruth B Caldwell; M Ali Behzadian
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

4.  Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).

Authors:  Boris K Pliyev
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

5.  Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion.

Authors:  Jamal Stie; Deborah Fox
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

6.  Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes?

Authors:  Ralf E Harskamp; Matthew T Roe
Journal:  J Am Heart Assoc       Date:  2014-10-23       Impact factor: 5.501

7.  The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.

Authors:  Nergiz Erkut; Ahmet Menteşe; Hasan Mücahit Özbaş; Nilay Ermantaş; Ayşegül Sümer; Asım Örem; Mehmet Sönmez
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

8.  Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.

Authors:  Tomasz W Kamiński; Krystyna Pawlak; Małgorzata Karbowska; Michał Myśliwiec; Dariusz Pawlak
Journal:  BMC Nephrol       Date:  2017-01-25       Impact factor: 2.388

9.  Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.

Authors:  Waldemar Gozdzik; Barbara Adamik; Anna Gozdzik; Maciej Rachwalik; Wojciech Kustrzycki; Andrzej Kübler
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

Review 10.  Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.

Authors:  Andreas Kronbichler; Moin A Saleem; Björn Meijers; Jae Il Shin
Journal:  J Immunol Res       Date:  2016-07-18       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.